AVEO Quote, Trading Chart, AVEO Pharmaceuticals Inc.
home / stock / aveo / aveo quote
$6.74 Last:
-4.26% Change Percent:
$6.98 Open:
$6.74 Previous Close:
$7.01 High:
$6.685 Low:
498,349 Volume:
06/21/2021 04:42:39 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
AVEO Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-06-21 | 6.98 | 6.74 | 7.01 | 6.685 | 498,349 |
| 2021-06-18 | 6.64 | 7.04 | 7.08 | 6.64 | 1,147,226 |
| 2021-06-17 | 6.81 | 6.64 | 6.93 | 6.57 | 616,034 |
| 2021-06-16 | 6.97 | 6.83 | 7.0208 | 6.65 | 482,524 |
| 2021-06-15 | 7.03 | 7 | 7.07 | 6.81 | 402,593 |
| 2021-06-14 | 7.24 | 7.04 | 7.37 | 7.01 | 416,361 |
| 2021-06-11 | 7.2 | 7.21 | 7.23 | 7.05 | 331,393 |
| 2021-06-10 | 7.25 | 7.21 | 7.35 | 7.1249 | 332,409 |
| 2021-06-09 | 7.26 | 7.27 | 7.585 | 7.22 | 487,627 |
| 2021-06-08 | 7.24 | 7.23 | 7.2999 | 7.01 | 375,078 |
| 2021-06-07 | 7.24 | 7.19 | 7.3802 | 7.15 | 393,146 |
| 2021-06-04 | 7.47 | 7.2 | 7.49 | 7.18 | 245,930 |
| 2021-06-03 | 7.22 | 7.3 | 7.49 | 7.22 | 259,620 |
| 2021-06-02 | 7.46 | 7.34 | 7.54 | 7.12 | 350,916 |
| 2021-06-01 | 7.29 | 7.45 | 7.565 | 7.1649 | 351,203 |
| 2021-05-31 | 7.19 | 7.3 | 7.38 | 7.15 | 368,182 |
| 2021-05-28 | 7.19 | 7.3 | 7.38 | 7.15 | 367,703 |
| 2021-05-27 | 6.93 | 7.14 | 7.26 | 6.85 | 392,647 |
| 2021-05-26 | 6.76 | 6.93 | 7 | 6.76 | 286,479 |
| 2021-05-25 | 6.87 | 6.78 | 6.97 | 6.75 | 366,762 |
AVEO Pharmaceuticals Inc. Company Name:
AVEO Stock Symbol:
NASDAQ Market:
News, Short Squeeze, Breakout and More Instantly...
-
Webinar on Wednesday, June 16 at 2:00 p.m. Eastern Time AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will host a key opinion leader webinar focusing on ficlatuzumab, the Company’s investig...
-
- Patients Treated with Tivozanib in TIVO-3 Study Demonstrated Over 20 Months Median DOR; OS Relative to Sorafenib Continues to Improve with Longer Follow-up - - Analysis of TEAEs in TIVO-3 Study Shows Longer Time to Onset and Fewer Dose Reductions for TEAEs for Tivozanib Comp...
-
– Study Achieved Primary Endpoint of mPFS in Patients Treated with Ficlatuzumab/Cetuximab (ERBITUX ® ) Combination – – 38% ORR, Including 13% CRs and 25% PRs, and Median PFS of 4.1 months Observed in HPV Negative Patients Treated with Ficlatuzumab...